

Nanoparticles in the Treatment of Virus- A Broad Study

Sabina Yeasmin*

Department of Polymer Science & Technology, University of Calcutta, Kolkata, India

*Correspondence to: Sabina Yeasmin, Department of Polymer Science & Technology, University of Calcutta, Kolkata, India; E-mail: sabina.kolkata21@gmail.com

Received: June 09, 2026; Manuscript No: JNNC-26-2529; Editor Assigned: June 11, 2026; PreQc No: JNNC-26-2529(PQ); Reviewed: June 23, 2026, 2026; Revised: August 25, 2026; Manuscript No: JNNC-26-2529(R); Published: October 01, 2026

Citation: Yeasmin S (2026). Nanoparticles in the Treatment of Virus- A Broad Study. J. Nanosci. Nanomater. Vol.2 Iss.1, October (2026), pp:85-91.

Copyright: © 2026 Sabina Yeasmin. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Viruses impact on healthcare and socioeconomic development. In a public health care system drug resistance are currently are available different therapies. Adverse side effects due to prolonged use is a serious public health concern. Novel treatment strategies developed. The interactions of nanostructures with microorganisms is fast revolutionizing the biomedical field by offering advantages in both diagnostic and therapeutic applications. Nanoparticles have unique properties that can help in drug delivery. The properties of nanoparticles that depend on others are particle size distribution, surface to volume ratio and surface charge depend on encapsulation. This properties can make nanoparticle drug delivery systems to explore therapeutic effects. This review present how to treat viral infections with nanosized materials.

Keywords: Nanosized Materials; Liposomes; Micelles; Viral Infection; Gold Nanoparticles

INTRODUCTION

Infectious disease agents such as bacteria, viruses, fungi and parasites account for approximately 15 million deaths worldwide, with acute respiratory infection and human immunodeficiency virus (HIV) being the leading causes [1,2]. Viral infections can help in both health and socioeconomic development [3]. Drug resistance evolved as it is associated with HIV and influenza infection [4-8]. This phenomenon included morbidity and mortality added costs associated with the use of more expensive drugs and a greater burden to public health systems [2,9]. A novel method develop to treat viral infections.

Nanoparticles are particles that belong to the nanometer range [10,11]. The interaction between nanoscience and biological systems is known as nanobiotechnology [12,13]. It is associated with nanomedicine and diagnose, treatment and prevention of diseases [14].

We are going to introduce here dose limiting biocompatible drugs [15]. For its small size it can invade cell easily [11,16]. Large surface area to volume ratio, surface charge make it a strong weapon to treat viral infections [17,18,19]. Nanoparticles also have some anti-viral properties [20-24]. It also can act as dendrimers [25,26]. It can be able to formation of stable structure [27,28]. It can also modified the structure of polymers [29]. It can also increase stability and the drug retention times [30,31]. This nanoparticles can invade cell and act in the cellular components [30,31,32]. Nanoparticle act as a drug carrier in case of RNA system also. It will act as a carrier

in the blood-brain barrier also. It leads to low level replication [33,34]. It also can invade the obstacle and act as a promising tool against membranes [35]. To invade all this problem RNA technology is necessary [36]. The inability of RNA to cross the cell membrane, due to large molecular weight and anionic charge rapid renal clearance, uptake by phagocytes, and toxicity due to stimulated immune response [37,38,39] all present limitations which prohibits their clinical utility. This review will provide an overview of the most recent and relevant literature that describes the application of nanotechnology for the treatment of common viral infections.

Biocompatible Systems

Organic nanoparticles

Organic nanoparticles are most common nanoparticle in drug delivery in humans [40-43]. The most common types of organic nanoparticles are presented below

Polymeric nanoparticles

Polymeric nanoparticles are particles ranging in size from 10-1000 nm. The small size result in capillary penetrations at target sites [44-49]. Polymers approved by the WHO and FDA use in medicine and pharmaceuticals include PLA, PGA and PLGA [50]. PLG and PLGA based nanoparticles are used for biocompatibility and biodegradability purposes [51]. It can interact with serum proteins decrease the opsonization [52,53]. The pharmacokinetic profile and gold-standard of cloaking agent systems can also be represented here [54,55]. Polymeric

nanoparticles can be classified as nanocapsules and nanospheres.



Figure 1: Polymeric Nanoparticle Shaped in Spherical Structure

Nanocapsules

In nanocapsules the drug get loaded in the hollow capsules of the inner cavity of polymer. This is coated by some coating range in size from 50 to 300 nm [56]. Nanocapsules can be used as an antiviral agents to cross blood brain barrier [33].




Figure 2: Structure of Nanocapsule

Nanospheres

Nanospheres are matrix that are uniformly dispersed within the size range of 100-200 nm in diameter [56,57]. Hepatitis B virus (HBV), herpes simplex virus (HSV) and influenza are treated by nanospheres [58-62].




Figure 3: Structure of Nanosphere

Liposomes

Liposomes are spherical carriers ranging in size from 20-30 nm [63]. A phospholipid bilayer is there contain an aqueous core

[64]. Hydrophilic and lipophilic drugs can also be incorporated into the phospholipid bilayer [65]. It can also be act as an immunological parts [66].

Micelles

Micelles are ranging in size from 10 -100 nm [57]. Polymeric micelles are working as drug delivery agents which have significant therapeutic potential [67-69]. Drug encapsulation with polymeric micelles is one of the most attractive nanotechnologies used to improve both the water solubility and stability of limited drugs [70].

Dendrimers

Dendrimers are symmetrical, macromolecular and hyper-branched structure having connectors and branching units that target environment is controlled by the terminal groups [71]. Central core, branches and functional groups can have the ability to display multivalent surface [72].

Solid Lipid Nanoparticles

Solid lipid nanoparticles are alternative drug delivery system to the conventional colloidal nanoparticles. It can also combine with other nanoparticles and uses in drug delivery systems. Large-scale production of polymeric nanoparticles is a major challenge, production is cost-effective [73]. Stability, safety, availability, decreased toxicity can improve drug-profiles in compared to synthetic polymer nanoparticles [74-76].

Inorganic Nanoparticles

Inorganic nanoparticles are smaller in size than organic nanoparticles [35]. The top-down approach uses chemical or physical methods to reduce the inorganic material to its nanosized form [77].



Figure 4: Structure of Inorganic Nanoparticle

Gold Nanoparticles

Gold nanoparticles (GNPs) are widely researched as nanocarriers due to their excellent conductivity flexibility of surface modification, biocompatibility, and simplistic preparation methods [78]. The unique physical and chemical properties include the gold core, nanotophysical properties and thiol linkages [79,80,81]. During GNPs preparation it can produce versatile ranges of nanoparticles [82-87].




Figure 5: Spherical Structure of Gold Nanoparticles

Silver Nanoparticles

Silver nanoparticles are the most effective of the metallic nanoparticles against bacteria, viruses and other eukaryotic microorganisms, particularly due to the inherent inhibitory and bactericidal potential of silver, but also because of their good conductivity, catalytic properties, and chemical stability [88,89]. The key mechanisms of action of silver nanoparticles are the release of silver ions (which enhances antimicrobial activity), cell membrane disruption, and DNA damage. The reader is referred to a detailed review on the application of silver nanoparticles as virucidal agents [90,91,92].



Figure 6: Structure of Silver Nanoparticles

Other metallic nanoparticles

Various other metallic nanoparticles such as titanium, zinc, and copper, as well as metal oxide nanoparticles such as iron oxide, zinc oxide, and titanium dioxide have demonstrated specific antiviral activities. Others, like platinum nanoparticles, which are used for the detection of influenza virus, are yet to be evaluated [93-97].

Virology

All these nanoparticles are used for the treatment of different viruses [98-103].

	Company	Description	Mechanism of action	Indication	Approval year/ stage of development	Reference
Inflexal V®	Crucell, Berna Biotech	Virosomal (150 nm liposomes) vaccine	Mimicking native antigen presentation: Liposomes mimic the native virus structure, thus allowing for cellular entry and membrane fusion. Retention of the natural presentation of antigens on liposomal surface provides for high immunogenicity.	Influenza	1997	Herzog, Mischler, Metcalfe, Bachmann and Jennings [104-106]
Epaxal®	Crucell, Berna Biotech	Inactivated virosomal (liposome) vaccine	Unique mechanism of action which mimics the natural process	HAV	1999	Bovier [107]
PegIntron®	Merck	PEGylated interferon alfa-2b	Improved stability of protein through PEGylation	HCV	2001	Alconcel [108]
Pegasys®	Genentech	PEGylated interferon alfa-2b	Improved stability of protein through PEGylation	HBV, HCV	2002	Alconcel [108]

Influvac® Plus	Solvay Pharma/ Abbott	Virosome vaccine	Containing influenza surface proteins neuraminidase and hemagglutinin	Influenza	2005	Waknine [109]
Fluquit™ (STP 702)	Sirnaomics Inc.	Short interfering RNA (SiRNA) therapeutic	Gene silencing	H5N1 and H1N1 influenza	Preclinical evaluation	Sirnaomics [110]
Cervisil® (STP 909)	Sirnaomics Inc.	Short interfering RNA (SiRNA) therapeutic	Gene silencing	HPV	Preclinical evaluation	Sirnaomics [110]
VivaGel® (SPL 7013)	Starpharma	Dendrimer	Lysine-based dendrimer with naphthalene disulfonic acid surface groups	HIV, HSV	Clinical trial (number: NCT00 740584) (approved for used against bacterial vaginosis)	Starpharma [111]
DermaVir	Genetic Immunity	Therapeutic vaccine	Synthetic plasmid DNA immunogen expressing 15 antigens, inducing significant expansions of the HIV-specific precursor/ memory T cell pool.	HIV	Clinical trial (number NCT00270205)	Rodriguez [112]
Doravirine (MK-1439)	Merck	Solid drug nanoparticle formulation	Non-nucleoside reverse transcriptase inhibitor	HIV	Clinical trial (number: NCT02 549040)	Molina [113]
ARB-001467 TKM-HBV	Arbutus Biopharma	Wet lipid nanoparticle	Lipid particle containing three RNAi therapeutics that target three sites on the HBV genome	HBV	Clinical trial (number: NCT02 631096)	Seto [114]

CONCLUSION

We can conclude that nanoparticles have antiviral effect also. For its small size it can invade cell easily. The system use for the synthesis of nanoparticles are extremely retain its property on the nanoparticles. Shape is generally spherical. It can invade cell and help in the treatment. We are providing here a lot of result that can reduce silver, gold particles and make them nanoparticles. Spherical nanoparticles have antiviral effect proven in this review. They can cure many diseases. Once it prepared stored in a dark place. So that it stay good for a long time. If you want to cure viral diseases you can use plant extracts for the preparation of nanoparticles. Will you ever seen

such a different type of nanoparticles synthesis and characterization medication and cure for the patient.

REFERENCES

1. Panáček A, Kolář M, Večeřová R, Pucek R, Soukupová J, Kryštof V, et al. Antifungal activity of silver nanoparticles against *Candida* spp. *Biomaterials*. 2009;30(31):6333-6340.
2. Qasim M, Lim DJ, Park H, Na D. Nanotechnology for diagnosis and treatment of infectious diseases. *J Nanosci Nanotechnol*. 2014;14(10):7374-7387.
3. Mehendale R, Joshi M, Patravale VB. Nanomedicines for treatment of viral diseases. *Crit Rev Ther Drug Carrier Syst*. 2013;30(1):149.

4. Little SJ, Holte S, Routy JP, Mayer KH, Connors M, Walker BD, et al. Antiretroviral-drug resistance among patients recently infected with HIV. *N Engl J Med*. 2002;347(6):385-394.
5. Shafer RW, Rhee SY, Pillay D, Miller V, Sandstrom P, Schapiro JM, et al. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. *AIDS*. 2007;21(2):215-223.
6. Lockhat HA, Silva JR, Alves CN, Lameira J. Binding free energy calculations of nine FDA-approved protease inhibitors against HIV-1 subtype C I36T† containing 100 amino acids per monomer. *Chem Biol Drug Des*. 2016;87(4):487-498.
7. Maseko SB, Natarajan S, Sharma V, Bhattacharyya N, Govender T, Sayed Y, et al. Purification and characterization of naturally occurring HIV-1 (South African subtype C) protease mutants from inclusion bodies. *Protein Expr Purif*. 2016;122:90-96.
8. Hayden F. Developing new antiviral agents for influenza treatment: what does the future hold? *Clin Infect Dis*. 2009;48(Suppl 1):S3-S13.
9. Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. *Clin Infect Dis*. 2006;42(Suppl 2):S82-S89.
10. Nalwa HS, editor. Handbook of nanostructured materials and nanotechnology. Vol. 1. San Diego: Academic Press; 1999. p. 1-3.
11. Parboosing R, Maguire GE, Govender P, Kruger HG. Nanotechnology and the treatment of HIV infection. *Viruses*. 2012;4(4):488-520.
12. Scheller FW, Bier FF, Pfeiffer D. Biosensoren: Grundlagen und Anwendungen. *Tech Mess*. 1995;62(1):213-219.
13. Niemeyer CM, Mirkin CA, editors. Nanobiotechnology: concepts, applications and perspectives. Vol. 1. Weinheim: Wiley-VCH; 2004.
14. Medepalli KK. Advanced nanomaterials for biomedical applications dissertation. Cambridge: ProQuest; 2008.
15. Schütz CA, Juillerat-Jeanneret L, Mueller H, Lynch I, Riediker M. Therapeutic nanoparticles in clinics and under clinical evaluation. *Nanomedicine (Lond)*. 2013;8(3):449-467.
16. Kumar A, Ma H, Zhang X, Huang K, Jin S, Liu J, et al. Gold nanoparticles functionalized with therapeutic and targeted peptides for cancer treatment. *Biomaterials*. 2012;33(4):1180-1189.
17. McNeil SE. Unique benefits of nanotechnology to drug delivery and diagnostics. *Methods Mol Biol*. 2011;697:3-8.
18. Caron J, Reddy LH, Lepêtre-Mouelhi S, Wils P, Desmaële D, Couvreur P. Squalenoyl nucleoside monophosphate nanoassemblies: new prodrug strategy for the delivery of nucleotide analogues. *Bioorg Med Chem Lett*. 2010;20(9):2761-2764.
19. Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. *Nat Rev Drug Discov*. 2010;9(8):615-627.
20. Gagliardi M. Biomimetic and bioinspired nanoparticles for targeted drug delivery. *Ther Deliv*. 2017;8(5):289-299.
21. Sanvicens N, Marco MP. Multifunctional nanoparticles - properties and prospects for their use in human medicine. *Trends Biotechnol*. 2008;26(8):425-433.
22. Bowman MC, Ballard TE, Ackerson CJ, Feldheim DL, Margolis DM, Melander C. Inhibition of HIV fusion with multivalent gold nanoparticles. *J Am Chem Soc*. 2008;130(22):6896-6897.
23. Sun RW, Chen R, Chung NP, Ho CM, Lin CL, Che CM. Silver nanoparticles fabricated in Hepes buffer exhibit cytoprotective activities toward HIV-1 infected cells. *Chem Commun (Camb)*. 2005;40:5059-5061.
24. Lara HH, Ayala-Núñez NV, Ixtepan-Turrent L, Rodríguez-Padilla C. Mode of antiviral action of silver nanoparticles against HIV-1. *J Nanobiotechnology*. 2010;8:1.
25. Mallipeddi R, Rohan LS. Progress in antiretroviral drug delivery using nanotechnology. *Int J Nanomedicine*. 2010;5:533-547.
26. Wang W, Guo Z, Chen Y, Liu T, Jiang L. Influence of generation 2-5 of PAMAM dendrimer on the inhibition of Tat peptide/TAR RNA binding in HIV-1 transcription. *Chem Biol Drug Des*. 2006;68(6):314-318.
27. Chiappetta DA, Facorro G, de Celis ER, Sosnik A. Synergistic encapsulation of the anti-HIV agent efavirenz within mixed poloxamine/poloxamer polymeric micelles. *Nanomedicine*. 2011;7(5):624-637.
28. Goldberg M, Langer R, Jia X. Nanostructured materials for applications in drug delivery and tissue engineering. *J Biomater Sci Polym Ed*. 2007;18(3):241-268.
29. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. *Mol Pharm*. 2008;5(4):505-515.
30. Santos-Martinez MJ, Rahme K, Corbalan JJ, Faulkner C, Holmes JD, Tajber L, et al. Pegylation increases platelet biocompatibility of gold nanoparticles. *J Biomed Nanotechnol*. 2014;10(6):1004-1015.
31. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. *Cancer Res*. 1994;54(4):987-992.
32. Muthu MS, Singh S. Targeted nanomedicines: effective treatment modalities for cancer, AIDS and brain disorders. *Nanomedicine (Lond)*. 2009;4(1):105-118.
33. De Oliveira MP, Garcion E, Venisse N, Benoit JP, Couet W, Olivier JC. Tissue distribution of indinavir administered as solid lipid nanocapsule formulation in mdr1a (+/+) and mdr1a (-/-) CF-1 mice. *Pharm Res*. 2005;22(11):1898-1905.
34. Hellmuth J, Valcour V, Spudich S. CNS reservoirs for HIV: implications for eradication. *J Virus Erad*. 2015;1(2):67-71.
35. Mahajan SD, Aalinkel R, Law WC, Reynolds JL, Nair BB, Sykes DE, et al. Anti-HIV-1 nanotherapeutics: promises and challenges for the future. *Int J Nanomedicine*. 2012;7:5301-5314.
36. Duan L, Yan Y, Liu J, Wang B, Li P, Hu Q, et al. Target delivery of small interfering RNAs with vitamin E-coupled nanoparticles for treating hepatitis C. *Sci Rep*. 2016;6:24867.
37. Adesina SK, Akala EO. Nanotechnology approaches for the delivery of exogenous siRNA for HIV therapy. *Mol Pharm*. 2015;12(12):4175-4187.
38. Chen BM, Su YC, Chang CJ, Burnouf PA, Chuang KH, Chen CH, et al. Measurement of pre-existing IgG and IgM antibodies against polyethylene glycol in healthy individuals. *Anal Chem*. 2016;88(21):10661-10666.
39. Toub N, Malvy C, Fattal E, Couvreur P. Innovative nanotechnologies for the delivery of oligonucleotides and siRNA. *Biomed Pharmacother*. 2006;60(9):607-620.
40. Bawa R. Nanopharmaceuticals: nanopharmaceuticals. *Eur J Nanomed*. 2010;3(1):34-40.
41. Walsh TJ, Viviani MA, Arathoon E, Chiou C, Ghannoum M, Groll AH, et al. New targets and delivery systems for antifungal therapy. *Med Mycol*. 2000;38(Suppl 1):335-347.
42. Dobrovolskaia MA, McNeil SE. Immunological properties of engineered nanomaterials. *Nat Nanotechnol*. 2007;2(8):469-478.
43. Zazo H, Colino CI, Lanao JM. Current applications of nanoparticles in infectious diseases. *J Control Release*. 2016;224:86-102.
44. Mora-Huertas CE, Fessi H, Elaissari A. Polymer-based nanocapsules for drug delivery. *Int J Pharm*. 2010;385(1-2):113-142.
45. Baram-Pinto D, Shukla S, Richman M, Gedanken A, Rahimipour S, Sarid R. Surface-modified protein nanospheres as potential antiviral agents. *Chem Commun (Camb)*. 2012;48(66):8359-8361.
46. Bergeron MG, Desormeaux A. Liposomes encapsulating antiviral drugs. US Patent 5,773,027. 1998.
47. Dutta T, Agashe HB, Garg M, Balasubramaniam P, Kabra M, Jain NK. Poly (propyleneimine) dendrimer based nanocontainers for

- targeting of efavirenz to human monocytes/macrophages in vitro. *J Drug Target.* 2007;15(1):89-98.
48. Giljohann DA, Seferos DS, Daniel WL, Massich MD, Patel PC, Mirkin CA. Gold nanoparticles for biology and medicine. *Angew Chem Int Ed Engl.* 2010;49(19):3280-3294.
 49. Ocheke NA, Olorunfemi PO, Ngwuluka NC. Nanotechnology and drug delivery part 2: nanostructures for drug delivery. *Trop J Pharm Res.* 2009;8(3):275-287.
 50. Stevanovic M, Uskokovic D. Poly (lactide-co-glycolide)-based micro and nanoparticles for the controlled drug delivery of vitamins. *Curr Nanosci.* 2009;5(1):1-14.
 51. Zhao L, Seth A, Wibowo N, Zhao CX, Mitter N, Yu C, et al. Nanoparticle vaccines. *Vaccine.* 2014;32(3):327-337.
 52. Aggarwal P, Hall JB, McClelland CB, Dobrovolskaia MA, McNeil SE. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. *Adv Drug Deliv Rev.* 2009;61(6):428-437.
 53. Kovochich M, Marsden MD, Zack JA. Activation of latent HIV using drug-loaded nanoparticles. *PLoS One.* 2011;6(4):e18270.
 54. Santos-Magalhães NS, Mosqueira VCF. Nanotechnology applied to the treatment of malaria. *Adv Drug Deliv Rev.* 2010;62(5):560-575.
 55. Mignani S, Majoral JP. Dendrimers as macromolecular tools to tackle from colon to brain tumor types: a concise overview. *New J Chem.* 2013;37(11):3337-3357.
 56. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. *J Control Release.* 2001;70(1-2):1-20.
 57. Letchford K, Burt H. A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes. *Eur J Pharm Biopharm.* 2007;65(3):259-269.
 58. Zeng P, Xu Y, Zeng C, Ren H, Peng M. Chitosan-modified poly (D, L-lactide-co-glycolide) nanospheres for plasmid DNA delivery and HBV gene-silencing. *Int J Pharm.* 2011;415(1-2):259-266.
 59. Dehghan S, Kheiri MT, Tabatabaiean M, Darabi S, Tafaghodi M. Dry-powder form of chitosan nanospheres containing influenza virus and adjuvants for nasal immunization. *Arch Pharm Res.* 2013;36(8):981-992.
 60. Mohajer M, Khameneh B, Tafaghodi M. Preparation and characterization of PLGA nanospheres loaded with inactivated influenza virus, CpG-ODN and Quillaja saponin. *Iran J Basic Med Sci.* 2014;17(9):722-726.
 61. Gregory AE, Williamson D, Titball R. Vaccine delivery using nanoparticles. *Front Cell Infect Microbiol.* 2013;3:13.
 62. Thorley AJ, Tetley TD. New perspectives in nanomedicine. *Pharmacol Ther.* 2013;140(2):176-185.
 63. Kuntworbe N, Martini N, Shaw J, Al-Kassas R. Malaria intervention policies and pharmaceutical nanotechnology as a potential tool for malaria management. *Drug Dev Res.* 2012;73(4):167-184.
 64. Amin R. Nanotechnology in controlling infectious disease. In: Hunter RJ, Preedy VR, editors. *Nanomedicine in health and disease.* Enfield, NH: Science Publishers; 2011. p. 167-183.
 65. Garnett MC. Targeted drug conjugates: principles and progress. *Adv Drug Deliv Rev.* 2001;53(2):171-216.
 66. Perrie Y, Mohammed AR, Kirby DJ, McNeil SE, Bramwell VW. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. *Int J Pharm.* 2008;364(2):272-280.
 67. Kabanov AV, Batrakova EV, Alakhov VY. Pluronic® block copolymers as novel polymer therapeutics for drug and gene delivery. *J Control Release.* 2002;82(2-3):189-212.
 68. Arifin DR, Palmer AF. Polymersome encapsulated hemoglobin: a novel type of oxygen carrier. *Biomacromolecules.* 2005;6(4):2172-2181.
 69. Zhang L, Gu F, Chan J, Wang A, Langer R, Farokhzad O. Nanoparticles in medicine: therapeutic applications and developments. *Clin Pharmacol Ther.* 2008;83(5):761-769.
 70. Moretton MA, Glisoni RJ, Chiappetta DA, Sosnik A. Molecular implications in the nanoencapsulation of the anti-tuberculosis drug rifampicin within flower-like polymeric micelles. *Colloids Surf B Biointerfaces.* 2010;79(2):467-479.
 71. Sahoo SK, Labhasetwar V. Nanotech approaches to drug delivery and imaging. *Drug Discov Today.* 2003;8(24):1112-1120.
 72. Caminade AM, Laurent R, Majoral JP. Characterization of dendrimers. *Adv Drug Deliv Rev.* 2005;57(15):2130-2146.
 73. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. *Eur J Pharm Biopharm.* 2000;50(1):161-177.
 74. Gupta U, Jain NK. Non-polymeric nano-carriers in HIV/AIDS drug delivery and targeting. *Adv Drug Deliv Rev.* 2010;62(4-5):478-490.
 75. Patel PA, Patravale VB. AmbiOnp: solid lipid nanoparticles of amphotericin B for oral administration. *J Biomed Nanotechnol.* 2011;7(5):632-639.
 76. Xie S, Tao Y, Pan Y, Qu W, Cheng G, Huang L, et al. Biodegradable nanoparticles for intracellular delivery of antimicrobial agents. *J Control Release.* 2014;187:101-117.
 77. Thakkar KN, Mhatre SS, Parikh RY. Biological synthesis of metallic nanoparticles. *Nanomedicine.* 2010;6(2):257-262.
 78. Cui Y, Zhao Y, Tian Y, Zhang W, Lü X, Jiang X. The molecular mechanism of action of bactericidal gold nanoparticles on *Escherichia coli*. *Biomaterials.* 2012;33(7):2327-2333.
 79. Connor EE, Mwamuka J, Gole A, Murphy CJ, Wyatt MD. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. *Small.* 2005;1(3):325-327.
 80. Skirtach AG, Muñoz Javier A, Kreft O, Köhler K, Piera Alberola A, Möhwald H, et al. Laser-induced release of encapsulated materials inside living cells. *Angew Chem Int Ed Engl.* 2006;45(28):4612-4617.
 81. Ghosh P, Han G, De M, Kim CK, Rotello VM. Gold nanoparticles in delivery applications. *Adv Drug Deliv Rev.* 2008;60(11):1307-1315.
 82. Schmid G. Large clusters and colloids. *Metals in the embryonic state.* *Chem Rev.* 1992;92(8):1709-1727.
 83. Brust M, Walker M, Bethell D, Schiffrin DJ, Whyman R. Synthesis of thiol-derivatised gold nanoparticles in a two-phase liquid-liquid system. *J Chem Soc Chem Commun.* 1994;(7):801-802.
 84. Templeton AC, Wuelfing WP, Murray RW. Monolayer-protected cluster molecules. *Acc Chem Res.* 2000;33(1):27-36.
 85. Turkevich J, Stevenson PC, Hillier J. A study of the nucleation and growth processes in the synthesis of colloidal gold. *Discuss Faraday Soc.* 1951;11:55-75.
 86. Frens G. Controlled nucleation for the regulation of the particle size in monodisperse gold suspensions. *Nature.* 1973;241(105):20-22.
 87. Grabar KC, Freeman RG, Hommer MB, Natan MJ. Preparation and characterization of Au colloid monolayers. *Anal Chem.* 1995;67(4):735-743.
 88. Gong P, Li H, He X, Wang K, Hu J, Tan W, et al. Preparation and antibacterial activity of Fe₃O₄@Ag nanoparticles. *Nanotechnology.* 2007;18(28):285604.
 89. Cho KH, Park JE, Osaka T, Park SG. The study of antimicrobial activity and preservative effects of nanosilver ingredient. *Electrochim Acta.* 2005;51(5):956-960.
 90. Rai M, Yadav A, Gade A. Silver nanoparticles as a new generation of antimicrobials. *Biotechnol Adv.* 2009;27(1):76-83.
 91. Huh AJ, Kwon YJ. 'Nanoantibiotics': a new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era. *J Control Release.* 2011;156(2):128-145.

92. Lara HH, Garza-Treviño EN, Ixtapan-Turrent L, Singh DK. Silver nanoparticles are broad-spectrum bactericidal and virucidal compounds. *J Nanobiotechnology*. 2011;9:30.
93. Gerrity D, Ryu H, Crittenden J, Abbaszadegan M. Photocatalytic inactivation of viruses using titanium dioxide nanoparticles and low-pressure UV light. *J Environ Sci Health A Tox Hazard Subst Environ Eng*. 2008;43(12):1261-1270.
94. Antoine TE, Mishra YK, Trigilio J, Tiwari V, Adelung R, Shukla D. Prophylactic, therapeutic and neutralizing effects of zinc oxide tetrapod structures against herpes simplex virus type-2 infection. *Antiviral Res*. 2012;96(3):363-375.
95. Ingle AP, Duran N, Rai M. Bioactivity, mechanism of action, and cytotoxicity of copper-based nanoparticles: a review. *Appl Microbiol Biotechnol*. 2014;98(3):1001-1009.
96. Yadavalli T, Shukla D. Role of metal and metal oxide nanoparticles as diagnostic and therapeutic tools for highly prevalent viral infections. *Nanomedicine (Lond)*. 2017;13(1):219-230.
97. Yang ZH, Zhuo Y, Yuan R, Chai YQ. An amplified electrochemical immunosensor based on in situ-produced 1-naphthol as electroactive substance and graphene oxide and Pt nanoparticles functionalized CeO₂ nanocomposites as signal enhancer. *Biosens Bioelectron*. 2015;69:321-327.
98. Chaudhuri RG, Paria S. Core/shell nanoparticles: classes, properties, synthesis mechanisms, characterization, and applications. *Chem Rev*. 2012;112(4):2373-2433.
99. Tojo C, Buceta D, López-Quintela MA. Core-shell nanocatalysts obtained in reverse micelles: structural and kinetic aspects. *J Nanomater*. 2015;2015:1-10.
100. Chatterjee K, Sarkar S, Rao KJ, Paria S. Core/shell nanoparticles in biomedical applications. *Adv Colloid Interface Sci*. 2014;209:8-39.
101. Cheong S, Ferguson P, Hermans IF, Jameson GN, Tilley RD. Synthesis and stability of highly crystalline and stable iron/iron oxide core/shell nanoparticles for biomedical applications. *ChemPlusChem*. 2012;77(2):135-140.
102. Varanda LC, Imaizumi M, Santos FJ, Jafelicci M. Iron oxide versus Fe₅₅Pt₄₅/Fe₃O₄: improved magnetic properties of core/shell nanoparticles for biomedical applications. *IEEE Trans Magn*. 2008;44(11):4448-4451.
103. Arias JL, López-Viota M, Ruiz MA, López-Viota J, Delgado AV. Development of carbonyl iron/ethylcellulose core/shell nanoparticles for biomedical applications. *Int J Pharm*. 2007;339(1-2):237-245.
104. Herzog C, Hartmann K, Künzi V, Kursteiner O, Mischler R, Lazar H, et al. Eleven years of Inflflexal® V – a virosomal adjuvanted influenza vaccine. *Vaccine*. 2009;27(33):4381-4387.
105. Mischler R, Metcalfe IC. Inflflexal V a trivalent virosome subunit influenza vaccine: production. *Vaccine*. 2002;20(Suppl 5):B17-B23.
106. Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. *Nat Rev Immunol*. 2010;10(11):787-796.
107. Bovier PA. Epaxal®: a virosomal vaccine to prevent hepatitis A infection. *Expert Rev Vaccines*. 2008;7(8):1141-1150.
108. Alconcel SNS, Baas AS, Maynard HD. FDA-approved poly(ethylene glycol)-protein conjugate drugs. *Polym Chem*. 2011;2(7):1442-1448.
109. Waknine Y. International approvals: Avalox IV, Pegasys, Influvac. Medscape. 2005.
110. Sirnaomics. Advancing RNAi therapeutics. 2016. Accessed November 24, 2016.
111. Starpharma. VivaGel active against Zika virus. 2016. Accessed October 10, 2016.
112. Rodriguez B, Asmuth DM, Matining RM, Spritzler J, Jacobson JM, MaWhinney S, et al. Safety, tolerability and immunogenicity of repeated doses of dermavir, a candidate therapeutic HIV vaccine, in HIV infected patients receiving combination antiretroviral therapy: results of the ACTG 5176 trial. *J Acquir Immune Defic Syndr*. 2013;64(4):351-359.
113. Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, et al. Doravirine is non-inferior to darunavir/r in phase 3 treatment-naïve trial at week 48. In: Program and abstracts of the 2017 Conference on Retroviruses and Opportunistic Infections (CROI 2017). Seattle, WA; February 13-16, 2017. Abstract 45LB.
114. Seto WK, Yuen MF. New pharmacological approaches to a functional cure of hepatitis B. *Clin Liver Dis*. 2016;8(4):83-88.